BIOMAT Database Logo BIOMAT Database Logo

Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. 1998

B Dahlöf, and R B Devereux, and S Julius, and S E Kjeldsen, and G Beevers, and U de Faire, and F Fyhrquist, and T Hedner, and H Ibsen, and K Kristianson, and O Lederballe-Pedersen, and L H Lindholm, and M S Nieminen, and P Omvik, and S Oparil, and H Wedel
Sahlgrenska University Hospital/Ostra, Göteborg, Sweden.

-Losartan was the first available orally administered selective antagonist of the angiotensin II type 1 receptor developed for the treatment of hypertension. The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study is a double-blind, prospective, parallel group study designed to compare the effects of losartan with those of the beta-blocker atenolol on the reduction of cardiovascular morbidity and mortality. Patients with essential hypertension, aged between 55 and 80 years, and ECG-documented left ventricular hypertrophy (LVH) were included. Altogether, 9223 patients in Scandinavia, the United Kingdom, and the United States were randomized from June 1995 through April 1997, and 9194 remain after exclusion of a study center at which irregularities were discovered. This population of hypertensives (mean systolic/diastolic blood pressure, 174.4/97.8 mm Hg) with LVH comprises women (54.1%) and men, mostly retired from active work (mean age, 66.9 years), with a high prevalence of overweight (mean body mass index, 28.0 kg/m2), diabetes mellitus (12.3%), lipid disorders (18.0%), and symptoms or signs of coronary heart disease (15.1%). There were fewer current smokers (<17%) than in the general population, and approximately 7% were nonwhite. Almost 30% of participants had been untreated for at least 6 months when screened for the study. Only 1557 persons who entered the placebo run-in period of 14 days were excluded, predominantly because of sitting blood pressures above or below the predetermined range of 160-200/95-115 mm Hg and ECG-LVH criteria not met. By application of simple 12-lead ECG criteria for LVH (Cornell voltage QRS duration product formula plus Sokolow-Lyon voltage read by a core laboratory), hypertensive patients with LVH with an average 5-year coronary heart disease risk of 22.3% according to the Framingham score were identified. This population is now being treated (goal, <140/90 mm Hg) in adherence with the protocol for at least 4 years after final enrollment (ie, through April 2001) and until at least 1040 patients suffer myocardial infarction, stroke, or cardiovascular death.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004562 Electrocardiography Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY. 12-Lead ECG,12-Lead EKG,12-Lead Electrocardiography,Cardiography,ECG,EKG,Electrocardiogram,Electrocardiograph,12 Lead ECG,12 Lead EKG,12 Lead Electrocardiography,12-Lead ECGs,12-Lead EKGs,12-Lead Electrocardiographies,Cardiographies,ECG, 12-Lead,EKG, 12-Lead,Electrocardiograms,Electrocardiographies, 12-Lead,Electrocardiographs,Electrocardiography, 12-Lead
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

B Dahlöf, and R B Devereux, and S Julius, and S E Kjeldsen, and G Beevers, and U de Faire, and F Fyhrquist, and T Hedner, and H Ibsen, and K Kristianson, and O Lederballe-Pedersen, and L H Lindholm, and M S Nieminen, and P Omvik, and S Oparil, and H Wedel
Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
November 2004, Expert opinion on pharmacotherapy,
B Dahlöf, and R B Devereux, and S Julius, and S E Kjeldsen, and G Beevers, and U de Faire, and F Fyhrquist, and T Hedner, and H Ibsen, and K Kristianson, and O Lederballe-Pedersen, and L H Lindholm, and M S Nieminen, and P Omvik, and S Oparil, and H Wedel
Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
August 2003, Circulation,
B Dahlöf, and R B Devereux, and S Julius, and S E Kjeldsen, and G Beevers, and U de Faire, and F Fyhrquist, and T Hedner, and H Ibsen, and K Kristianson, and O Lederballe-Pedersen, and L H Lindholm, and M S Nieminen, and P Omvik, and S Oparil, and H Wedel
Crumbling of left ventricular hypertrophy as a surrogate end point (the Losartan for Intervention for Endpoint Reduction in Hypertension [LIFE] Study).
November 2002, The American journal of cardiology,
B Dahlöf, and R B Devereux, and S Julius, and S E Kjeldsen, and G Beevers, and U de Faire, and F Fyhrquist, and T Hedner, and H Ibsen, and K Kristianson, and O Lederballe-Pedersen, and L H Lindholm, and M S Nieminen, and P Omvik, and S Oparil, and H Wedel
Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study.
January 2006, Journal of human hypertension,
B Dahlöf, and R B Devereux, and S Julius, and S E Kjeldsen, and G Beevers, and U de Faire, and F Fyhrquist, and T Hedner, and H Ibsen, and K Kristianson, and O Lederballe-Pedersen, and L H Lindholm, and M S Nieminen, and P Omvik, and S Oparil, and H Wedel
Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy.
August 2008, Hypertension (Dallas, Tex. : 1979),
B Dahlöf, and R B Devereux, and S Julius, and S E Kjeldsen, and G Beevers, and U de Faire, and F Fyhrquist, and T Hedner, and H Ibsen, and K Kristianson, and O Lederballe-Pedersen, and L H Lindholm, and M S Nieminen, and P Omvik, and S Oparil, and H Wedel
Losartan for LIFE in hypertension with left ventricular hypertrophy?
January 2003, Expert opinion on pharmacotherapy,
B Dahlöf, and R B Devereux, and S Julius, and S E Kjeldsen, and G Beevers, and U de Faire, and F Fyhrquist, and T Hedner, and H Ibsen, and K Kristianson, and O Lederballe-Pedersen, and L H Lindholm, and M S Nieminen, and P Omvik, and S Oparil, and H Wedel
An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
May 2007, Clinical therapeutics,
B Dahlöf, and R B Devereux, and S Julius, and S E Kjeldsen, and G Beevers, and U de Faire, and F Fyhrquist, and T Hedner, and H Ibsen, and K Kristianson, and O Lederballe-Pedersen, and L H Lindholm, and M S Nieminen, and P Omvik, and S Oparil, and H Wedel
Letter regarding article by Devereux et al, "regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial".
June 2005, Circulation,
B Dahlöf, and R B Devereux, and S Julius, and S E Kjeldsen, and G Beevers, and U de Faire, and F Fyhrquist, and T Hedner, and H Ibsen, and K Kristianson, and O Lederballe-Pedersen, and L H Lindholm, and M S Nieminen, and P Omvik, and S Oparil, and H Wedel
Psoriasis is associated with subsequent atrial fibrillation in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint study.
March 2014, Journal of hypertension,
B Dahlöf, and R B Devereux, and S Julius, and S E Kjeldsen, and G Beevers, and U de Faire, and F Fyhrquist, and T Hedner, and H Ibsen, and K Kristianson, and O Lederballe-Pedersen, and L H Lindholm, and M S Nieminen, and P Omvik, and S Oparil, and H Wedel
Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
April 2008, Hypertension (Dallas, Tex. : 1979),
Copied contents to your clipboard!